BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to assess the safety and efficacy of repeated
administrations of BoNT-A in subjects with NP attributable to carpal tunnel syndrome (CTS)
through a randomized, double-blind, placebo-controlled study. Further research has shown that
BoNT-A has analgesic properties independently from its action on muscle tone, possibly by
acting on neurogenic inflammation. Therefore, the study drug may be better than other
treatments surgical or non-surgical currently available for the treatment of CTS.